7-isoquinolinethiol | 663623-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 7-isoquinolinethiol
• 英文别名: Isoquinoline-7-thiol
• CAS: 663623-45-8
• 化学式: C₉H₇NS
• 分子量: 161.227
• InChiKey: SZFSSODKPIFYSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  13.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-isoquinolinethiol 在 盐酸 、 碳酸氢钠 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 (2-(isoquinolin-7-ylthio)ethyl)glycine hydrochloride
  参考文献：
  名称：

  Part 1: N-Alkylated glycines as potent α2δ ligands

  摘要：

  A new series of glycine-derived ligands of the alpha(2)delta subunit of voltage gated calcium channels is described. Several novel compounds (7) based on (6) were prepared that possessed a potency <100 nM in the alpha(2)delta binding assay. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.045
• 作为产物：
  描述：

  在 cesium fluoride 作用下， 生成 7-isoquinolinethiol
  参考文献：
  名称：

  Part 1: N-Alkylated glycines as potent α2δ ligands

  摘要：

  A new series of glycine-derived ligands of the alpha(2)delta subunit of voltage gated calcium channels is described. Several novel compounds (7) based on (6) were prepared that possessed a potency <100 nM in the alpha(2)delta binding assay. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.045

文献信息

• [EN] SUBSTITUTED GLYCINE DERIVATIVES FOR USE AS MEDICAMENTS<br/>[FR] DERIVES DE GLYCINE SUBSTITUES SERVANT DE MEDICAMENTS
  申请人：PFIZER LTD

  公开号：WO2004016583A1

  公开（公告）日：2004-02-26

  The compounds of formula (I) are substituted glycine derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. Formula (I) wherein R' is hydroxycarbonyl, a carboxylic acid biostere or prodrug thereof; R3, R3a, R2 and R2a are independently selected from H, C1-C6 alkyl, and Cl-C6 alkoxy Cl-C6 alkyl.

  公式(I)的化合物是取代甘氨酸衍生物，可用于治疗癫痫、晕厥发作、运动减少、颅脑疾病、神经退行性疾病、抑郁症、焦虑症、恐慌症、疼痛、关节炎、神经病理学疾病、睡眠障碍、内脏疼痛疾病和胃肠疾病。包括用于制备最终产品和在过程中有用的中间体的方法。还包含含有一种或多种化合物的药物组合物。公式(I)中，R'是羟碳酰基，羧酸的生物立体异构体或前药；R3、R3a、R2和R2a独立地选自H、C1-C6烷基和Cl-C6烷氧基Cl-C6烷基。
• [EN] INHIBITION OF OLIG2 ACTIVITY<br/>[FR] INHIBITION DE L'ACTIVITÉ D'OLIG2
  申请人：CURTANA PHARMACEUTICALS INC

  公开号：WO2018039621A1

  公开（公告）日：2018-03-01

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

  本文描述了含有这些化合物的化合物和药物组合物，这些化合物抑制Olig2的活性。本文还描述了使用这种Olig2抑制剂的方法，单独或与其他化合物结合，用于治疗癌症和其他疾病。特别是Olig2抑制剂可用于治疗胶质母细胞瘤。
• Substituted glycine derivatives for use as medicaments
  申请人：——

  公开号：US20040092498A1

  公开（公告）日：2004-05-13

  The compounds of formula (I) are substituted glycine derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. 1 wherein R 1 is hydroxycarbonyl, a carboxylic acid biostere or prodrug thereof; R 3 , R 3a , R 2 and R 2a are independently selected from H, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy C 1 -C 6 alkyl; Z is; (i) a C-linked, 5 membered heterocycloalky or heteroaryl substituted with C 1 -C 6 alkyl or fused with C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, or monocyclic heteroaryl, wherein the fused ring is optionally substituted with one or two substituents selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, perfluoro C 1 -C 6 alkyl, perfluoro C 1 -C 6 alkoxy, cyano, C 1 -C 6 alkyl amino, C 1 -C 6 alkyl thio, C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, and monocyclic heteroaryl; or (ii) the group; 2 wherein R 4 and R 4a are independently H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy or C 1 -C 6 alkoxy C 1 -C 6 alkyl; R 5 is C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, 4-12 membered heterocycloalkyl, aryl or heteroaryl and R 5 is optionally substituted with one or two substituents selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, perfluoro C 1 -C 6 alkyl, perfluoro C 1 -C 6 alkoxy, cyano, C 1 -C 6 alkyl amino, di-C 1 -C 6 alkyl amino, amino C 1 -C 6 alkyl, C 1 -C 6 alkyl amino C 1 -C 6 alkyl, di-C 1 -C 6 alkyl amino C 1 -C 6 alkyl, C 1 -C 6 alkyl thio, C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; and either; (i) Y is S, O, NH or CH 2 and X is a direct link or C 1 -C 2 alkyl optionally substituted with C 1 -C 6 alkyl or di-C 1 -C 6 alkyl or 1-4 fluorine atoms; or (ii) X is S, O, CH 2 or NH and Y is C 1 -C 2 alkyl optionally substituted with C 1 -C 6 alkyl or di-C 1 -C 6 alkyl or 1-4 fluorine atoms.

  公式（I）的化合物是取代的甘氨酸衍生物，用于治疗癫痫，晕厥发作，低动力症，颅内疾病，神经退行性疾病，抑郁症，焦虑症，惊恐症，疼痛，关节炎，神经病理学疾病，睡眠障碍，内脏疼痛疾病和胃肠疾病的治疗。包括制备最终产品和在过程中有用的中间体的过程。还包括含有一种或多种化合物的制药组合物。 其中，R1是羟基甲酰，羧酸生物立体异构体或其前药; R3，R3a，R2和R2a独立选择自H，C1-C6烷基和C1-C6烷氧基C1-C6烷基; Z是; (i) C-连接的，5个成员的杂环烷基或杂环芳基，用C1-C6烷基或与C3-C8环烷基融合，4-8个成员的杂环烷基，苯基或单环杂芳基取代，其中融合环可选地取代为卤素，C1-C6烷基，C1-C6烷氧基，全氟C1-C6烷基，全氟C1-C6烷氧基，氰基，C1-C6烷基氨基，C1-C6烷基硫基，C3-C8环烷基，4-8个成员的杂环烷基，苯基和单环杂芳基的两个取代基中的一种; 或 (ii) 该组; 其中，R4和R4a独立为H，C1-C6烷基，C1-C6烷氧基或C1-C6烷氧基C1-C6烷基; R5是C1-C6烷基，C3-C12环烷基，4-12个成员的杂环烷基，芳基或杂芳基，R5可选地取代为卤素，C1-C6烷基，C1-C6烷氧基，全氟C1-C6烷基，全氟C1-C6烷氧基，氰基，C1-C6烷基氨基，二C1-C6烷基氨基，氨基C1-C6烷基，C1-C6烷基氨基C1-C6烷基，二C1-C6烷基氨基C1-C6烷基，C1-C6烷基硫基，C3-C8环烷基，4-8个成员的杂环烷基，苯基和单环杂芳基的两个取代基中的一种; 并且要么; (i) Y是S，O，NH或CH2，X是直接链接或C1-C2烷基，可选地取代为C1-C6烷基或二C1-C6烷基或1-4个氟原子; 或 (ii) X是S，O， 或NH，Y是C1-C2烷基，可选地取代为C1-C6烷基或二C1-C6烷基或1-4个氟原子。
• [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS)
  申请人：Samsung Display Co., Ltd.

  公开号：EP3301097A2

  公开（公告）日：2018-04-04

  The present invention relates to benzo[4',5']thieno[3',2':4,5]imidazo[1,2-a]pyridine derivatives and related compounds for use in organic light emitting devices (OLEDs). The OLED includes at two electrodes and an organic layer disposed between the electrodes including a compound of the present invention. The compounds of the present invention are represented by Formula 1: in Formula 1, A11 is a C1-C60 heterocyclic group, A12 is a C5-C60 carbocyclic group or a C1-C60 heterocyclic group, X11 is O or S, X12 is C, X13 is selected from N, C, and C(R13), X14 is selected from N, C, and C(R14), and X13 and X14 are linked via a single bond or a double bond.

  本发明涉及用于有机发光器件（OLED）的苯并[4',5']噻吩并[3',2':4,5]咪唑并[1,2-a]吡啶衍生物及相关化合物。 OLED 包括两个电极和置于电极之间的有机层，有机层中包括本发明的化合物。 本发明的化合物由式 1 表示： 式 1 中，A11 是 C1-C60 杂环基团，A12 是 C5-C60 碳环基团或 C1-C60 杂环基团，X11 是 O 或 S，X12 是 C、 X13 选自 N、C 和 C(R13)、 X14 选自 N、C 和 C(R14)，且 X13 和 X14 通过单键或双键相连。
• DIAMINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
  申请人：Samsung Display Co., Ltd.

  公开号：EP3561894A1

  公开（公告）日：2019-10-30

  Provided are a diamine compound including a naphthyl-phenyl linker and a 2-carbazolyl group and an organic light-emitting device including the same. The organic light-emitting device includes: a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, wherein the organic layer includes the diamine compound including the naphthyl-phenyl linker and the 2-carbazolyl group.

  本发明提供了一种包括萘基-苯基连接体和 2-咔唑基团的二胺化合物，以及一种包括该二胺化合物的有机发光器件。有机发光器件包括：第一电极；第二电极；以及位于第一电极和第二电极之间并包括发射层的有机层，其中有机层包括二胺化合物，该二胺化合物包括萘基-苯基连接体和 2-咔唑基团。